68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

被引:239
|
作者
Poeppel, Thorsten D. [1 ]
Binse, Ina [1 ]
Petersenn, Stephan [2 ]
Lahner, Harald [2 ]
Schott, Matthias [3 ]
Antoch, Gerald [4 ]
Brandau, Wolfgang [1 ]
Bockisch, Andreas [1 ]
Boy, Christian [1 ]
机构
[1] Univ Essen Gesamthsch, Dept Nucl Med, Essen, Germany
[2] Univ Essen Gesamthsch, Dept Endocrinol, Essen, Germany
[3] Univ Dusseldorf, Dept Endocrinol, D-40225 Dusseldorf, Germany
[4] Univ Dusseldorf, Dept Diagnost & Intervent Radiol, D-40225 Dusseldorf, Germany
关键词
Ga-68-DOTATOC PET/CT; Ga-68-DOTATATE PET/CT; NET; RECEPTOR RADIONUCLIDE THERAPY; SOMATOSTATIN ANALOGS; PEPTIDE; SCINTIGRAPHY; CONTRAST; Y-90-DOTATOC; EXPRESSION; GUIDELINES; SST1-SST5; DOSIMETRY;
D O I
10.2967/jnumed.111.091165
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are Ga-68-DOTATATE and Ga-68-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of Ga-68-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of Ga-68-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs (Ga-68-DOTATATE and Ga-68-DOTATOC) in the same NET patients. Methods: Forty patients with metastatic NETs underwent Ga-68-DOTATOC and Ga-68-DOTATATE PET/CT as part of the work-up before prospective peptide receptor radionuclide therapy. The performance of both imaging methods was analyzed and compared for the detection of individual lesions per patient and for 8 defined body regions. A region was regarded positive if at least 1 lesion was detected in that region. In addition, radiopeptide uptake in terms of the maximal standardized uptake value (SUVmax) was compared for concordant lesions and renal parenchyma. Results: Seventy-eight regions were found positive with Ga-68-DOTATATE versus 79 regions with Ga-68-DOTATOC (not significant). Overall, however, significantly fewer lesions were detected with Ga-68-DOTATATE than with Ga-68-DOTATOC (254 vs. 262, P < 0.05). Mean Ga-68-DOTATATE SUVmax across all lesions was significantly lower than Ga-68-DOTATOC (16.0 +/- 10.8 vs. 20.4 +/- 14.7, P < 0.01). Mean SUVmax for renal parenchyma was not significantly different between Ga-68-DOTATATE and Ga-68-DOTATOC (12.7 +/- 3.0 vs. 13.2 +/- 3.3). Conclusion: Ga-68-DOTATOC and Ga-68-DOTATATE possess a comparable diagnostic accuracy for the detection of NET lesions, with Ga-68-DOTATOC having a potential advantage. The approximately 10-fold higher affinity for the sst2 of Ga-68-DOTATATE does not prove to be clinically relevant. Quite unexpectedly, SUVmax of Ga-68-DOTATOC scans tended to be higher than their Ga-68-DOTATATE counterparts.
引用
收藏
页码:1864 / 1870
页数:7
相关论文
共 50 条
  • [1] 68Ga-DOTATOC vs. 68Ga-DOTATATE PET/CT in functional imaging of Neuroendocrine Tumours
    Poeppel, T. D.
    Binse, I.
    Petersenn, S.
    Lahner, H.
    Schott, M.
    Antoch, G.
    Brandau, W.
    Bockisch, A.
    Boy, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S97 - S98
  • [2] Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors
    Sandstrom, Mattias
    Velikyan, Irina
    Garske-Roman, Ulrike
    Sorensen, Jens
    Eriksson, Barbro
    Granberg, Dan
    Lundqvist, Hans
    Sundin, Anders
    Lubberink, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (10) : 1755 - 1759
  • [3] Intrapatient 68Ga-DOTATOC/68Ga-DOTATATE uptake comparison in primary neuroendocrine tumors, metastases and normal liver
    Todorovic-Tirnanic, Mila
    Gajic, Milan
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [4] PET/CT using 68Ga-DOTATATE for imaging neuroendocrine tumors (NET)
    Amaral, Horacio
    Cecilia Gil, Maria
    Redondo, Francisca
    Lavados, Hugo
    Pruzzo, Rossana
    Coudeu, Irene
    Astudillo, Sergio
    Galaz, Rodrigo
    Baum, Richard
    Roesch, Frank
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [5] Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in Primary Neuroendocrine Tumors, Metastases, and Normal Liver Tissue - is there a Significant Difference?
    Todorovic-Tirnanic, M.
    Gajic, M.
    Baum, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S383 - S383
  • [6] Uptake of 68Ga-DOTATATE and 68Ga-DOTATOC in primary neuroendocrine tumors, metastases, and normal liver tissue: is there a significant difference?
    Todorovic-Tirnanic, M.
    Gajic, M. M.
    Baum, R. P.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [7] Meningiomas: A Comparative Study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for Molecular Imaging in Mice
    Luisa Soto-Montenegro, Maria
    Pena-Zalbidea, Santiago
    Maria Mateos-Perez, Jose
    Oteo, Marta
    Romero, Eduardo
    Angel Morcillo, Miguel
    Desco, Manuel
    PLOS ONE, 2014, 9 (11):
  • [8] Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors
    Anderson, Redmond-Craig
    Velez, Erik M.
    Desai, Bhushan
    Jadvar, Hossein
    NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 55 (01) : 31 - 37
  • [9] The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors
    Haug, Alexander
    Cindea-Drimus, Ramona
    Auernhammer, Christoph
    Schmidt, Gerwin
    Bartenstein, Peter
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [10] The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors
    Haug, Alexander R.
    Cindea-Drimus, Ramona
    Auernhammer, Christoph J.
    Reincke, Martin
    Waengler, Bjoern
    Uebleis, Christopher
    Schmidt, Gerwin P.
    Goeke, Burkhard
    Bartenstein, Peter
    Hacker, Marcus
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (11) : 1686 - 1692